Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 265-110-5 | CAS number: 64742-10-5 A complex combination of hydrocarbons obtained as the extract from a solvent extraction process. It consists predominantly of aromatic hydrocarbons having carbon numbers predominantly higher than C25.
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
There were no repeated dose inhalation studies identified.
Two key 90 -day oral studies (OECD 408) have been conducted, in one study (on CAS 91995 -70 -9) the NOAEL was determined to be 1000 mg/kg/day for both males and females. In the other study (on CAS 64742 -10 -5) possible relationship between test item and one unscheduled death (male at 1000 mg/kg/day) and microscopic findings in brain and spinal cord (females at 300 and 1000 mg/kg/day) meant the NOAEL was 100 and 300 mg/kg/day for females and males respectively.
A key 90-day dermal toxicity study (OECD 411) examined RAE substances in male and female rats and determined a NOAEL of 500 mg/kg/day for Mobilsol 40; however, a NOAEL could not be clearly established for the BSE Australia, Ninian and Statjford since only a single dose level was evaluated for these three extracts.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 100 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 500 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Additional information
There were no repeated dose inhalation studies identified.
There were two key studies for oral exposure, NOAELs were 1000 mg/kg/day in one study and 100 (females and 300 (males) mg/kg/day in the other study.
In a repeated dose dermal study, ten male and female [N(SD)fBR] rats were dosed dermally with four Bright Stock Extracts (BSEs) comprised of Mobilsol 40, BSE Australia, BSE Ninian, and BSE Statfjord 5 days/week for 13 weeks (Mobil, 1990). A group of ten male and female rats served as the control group. Prior to test material(s) application, each animal was clipped free of hair from the entire dorsal trunk area. Hair was re-clipped as required at least once per week. Mobilsol was applied at a dose of 500 and 2000 mg/kg-day, whereas, the other three BSE extracts were applied at a dose of 2000 mg/kg-day. The exposure sites were left uncovered. All treated and control rats were fitted with a cardboard Elizabethan-style collars lined with latex tubing to minimize ingestion of the test materials. Collars were fitted on the rats several days prior to dose administration and replaced as needed during the dosing period.
No signs of skin irritation were reported as a result of exposure to the four BSEs. No adverse clinical signs were attributed as a result of exposure to the test materials. Body weight gains were normal in all rats treated with the four BSEs. Urinalyses and sperm evaluations were not impacted as a result of exposure to the test materials. No histopathological changes were noted in the reproductive organs of male or female rats. Further, neither epididymal spermatozoa morphology and count nor testicular spermatid counts were affected by treatment with RAEs as shown in the table.
Table 1. Summaries of data on reproductive organs from subchronic studies with RAEs (CAS RN. 64742-10-5), derived from Mobil, 1990. |
|||
Test Material |
Route, Species, Doses, Exposure Regimen |
Endpoints |
Results |
Mobilsol 40
|
Dermal. Male and female rats. 0, 500, 2000 mg/kg on 5 d/wk for 13 wk. |
Full necropsy. Weights of testes, prostate, epididymides, ovaries, and uterus. Histopathology of testes and ovaries. Weight of testicular parenchyma and cauda epididymis. Number of testicular sperm and number/g testis. Number and morphology of epididymal sperm, number/g cauda. |
No treatment-related effect noted on reproductive organs. |
BSE - Australia |
Dermal. Male and female rats. 0, 2000 mg/kg on 5 d/wk for 13 wk. |
Full necropsy. Weights of testes, prostate, epididymides, ovaries, and uterus. Histopathology of testes and ovaries. Weight of testicular parenchyma and cauda epididymis. Number of testicular sperm and number/g testis. Number and morphology of epididymal sperm, number/g cauda. |
No treatment-related effect noted on reproductive organs. |
BSE – Ninian |
Dermal. Male rats. 2000 mg/kg on 5 d/wk for 13 wk. |
Full necropsy. Weights of testes, prostate, and epididymides. Histopathology of testes. |
No treatment-related effect noted on reproductive organs. |
BSE-Statfjord |
Dermal. Female rats. 2000 mg/kg on 5 d/wk for 13 wk. |
Full necropsy. Weights of ovaries and uterus. Histopathology of ovaries. |
No treatment-related effect noted on reproductive organs. |
Changes in haematological parameters were noted in treated females, but not males. At 13 weeks, significant decreases in haematological parameters, compared to the control group, were noted in red blood cells (RBCs) and haematocrit in females treated with Mobilsol 40, RBCs, haemoglobin, and haematocrit in BSE Australia, and RBC, haemoglobin, and haematocrit in BSE Statjford (only females were exposed for this BSE).
Mobilsol 40, BSE Statjford, and BSE Ninian slightly affected the normal serum chemistry of treated rats. The serum chemistry of animals exposed to BSE Australia was more adverse compared to animals exposed to other BSEs. In Mobilsol 40, glucose, albumin, calcium (in males), glucose, and sorbitol dehydrogenase (SDH) (females) were significantly different from the control group. Animals treated with BSE Australia showed significant differences in urea nitrogen, creatinine, total protein, albumin, albumin/globulin ratio and SDH (males) levels compared to the concurrent controls. Alkaline phosphatase, calcium, and SDH levels were significantly different compared to the controls in animals treated with BSE Statjford (only females were treated with this BSE). Animals treated with BSE Ninian (only male rats were exposed to this BSE) exhibited significant changes in uric acid, albumin, calcium, inorganic phosphorus, chloride, and SDH compared to the concurrent controls.
Liver weights of male rats treated with Mobilsol 40 were increased in the 2000 mg/kg-day group and in male and female rats treated with 2000 mg/kg-day BSE Australia. The study authors reported that the increase in liver weight was more of an adaptive response rather than an adverse effect.
Based on these results, the study authors concluded that the No-Observed-Adverse-Level (NOAEL) for Mobilsol 40 is 500 mg/kg-day. A LOEL of 2000 mg/kg-day was established for the BSE Australia, Ninian and Statjford but a NOAEL could not be established for these materials since only a single dose level was evaluated for these three extracts.
Justification for classification or non-classification
There were no repeated dose toxicity studies for inhalation exposure of RAEs.
There were two key studies for oral exposure, NOAELs were 1000 mg/kg/day in one study and 100 (females) and 300 (males) mg/kg/day in the other study.
There was one repeated dose toxicity study identified for dermal exposure. Based on the 90 -day dermal results, RAEs are not classified under CLP Regulation, (EC)1272/2008, based on a NOAEL for Mobilsol 40 of
500 mg/kg-day. A NOAELs could not be clearly established for the BSE Australia, Ninian and Statjford since only a single dose level was evaluated for these three extracts.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.